InxMed’s Ifebemtinib Secures the NMPA’s Breakthrough Therapy Designation as a 1L Treatment of KRAS G12C Mutated NSCLC
Shots:
- The NMPA has granted BTD to ifebemtinib (IN10018) plus garsorasib as a 1L treatment of KRAS G12C mutated NSCLC. InxMed is looking for partnership worldwide to develop ifebemtinib
- Designation was based on P-Ib/II trial of ifebemtinib + garsorasib, depicting ORR of 90.3%, DCR of 96.8%, mPFS not reached along with 28 confirmed PRs & 2 SDs in 31 efficacy evaluable patients. It also showed synergies with other cancer treatments, incl. anti-PD-(L)1 antibodies & RAS inhibitors
- InxMed is conducting a registrational trial for Pt-resistant ovarian cancer, with plans to file NDA to the NMPA in 2025. The company also has ongoing PoC studies in lung, colorectal, melanoma & pancreatic cancers, with some advancing to pivotal studies
Ref: InxMed | Image: InxMed
Related News:- InxMed Reveals Data from the P-Ib/II Study of Ifebemtinib Plus Garsorasib for Non-Small Cell Lung Cancer (NSCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
